Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data

JA Pasco; SE Lane; SL Brennan; EN Timney; G Bucki-Smith; AG Dobbins; GC Nicholson; MA Kotowicz

Journal article

Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data

JA Pasco, SE Lane, SL Brennan, EN Timney, G Bucki-Smith, AG Dobbins, GC Nicholson, MA Kotowicz

Osteoporosis International | SPRINGER LONDON LTD | Published : 2014

DOI: 10.1007/s00198-013-2561-9

University of Melbourne Researchers

Mark Kotowicz Author

Julie Pasco Author

Sharon Brennan-Olsen Author

Related Projects (2)

Male Osteoporosis: A Population Based Study In Geelong

Osteoporosis is a term used to indicate that bones have become thin and fragile. During the ageing process bone fragility increases and frac..

Bone Size And Bone Turnover: Relationship To Fracture Risk Over Ten Years

The occurrence of fracture in the ageing population is a major public health problem because these fractures are responsible for considerabl..

Grants

Awarded by National Health and Medical Council

Awarded by NHMRC

Funding Acknowledgements

The study was funded by grants from the National Health and Medical Council (NHMRC 299831, 628582), The University of Melbourne Research Grant Scheme, American Society for Bone and Mineral Research (ASBMR), Perpetual Trustees, Amgen and the Geelong Region Medical Research Foundation, but they played no part in the design or conduct of the study; collection, management, analysis and interpretation of the data; or in preparation, review or approval of the manuscript. JAP was a recipient of the grants from the NHMRC (projects #251638, #299831, #628582), Geelong Regional Medical Research Foundation, Arthritis Foundation of Australia and Amgen (Europe) GmBH. SLB was supported by NHMRC scholarship (#519404) and NHMRC Postdoctoral (Training) Fellowship (#1012472). GCN was a recipient of grants from the NHMRC (projects #251638, #299831, #628582) and Amgen (Europe) GmBH. MAK was a recipient of grants from the NHMRC (projects #251638, #299831, #628582), Geelong Regional Medical Research Foundation and Amgen (Europe) GmBH.